ConductScience.org, home
A Phase 3 Adaptive Study to Evaluate the Safety and Efficacy of Inhaled Treprostinil in Participants With Pulmonary Hypertension (PH) Due to Chronic Obstructive Pulmonary Disease (COPD)
API referenceFor AI assistants

Trial · NCT03496623

Participant flow60

How many started, completed or left each group, period by period.

1 to 20 of 60

Download this page as JSON
PeriodMilestoneGroupParticipantsUnits counted
Run-In Period (2 Weeks)STARTEDRun-In108
Run-In Period (2 Weeks)STARTEDOriginal Crossover Design - Treprostinil, Then Placebo0
Run-In Period (2 Weeks)STARTEDOriginal Crossover Design - Placebo, Then Treprostinil0
Run-In Period (2 Weeks)STARTEDContingent Parallel Design - Treprostinil0
Run-In Period (2 Weeks)STARTEDContingent Parallel Design - Placebo0
Run-In Period (2 Weeks)Received At Least 1 Dose of Study DrugRun-In108
Run-In Period (2 Weeks)Received At Least 1 Dose of Study DrugOriginal Crossover Design - Treprostinil, Then Placebo0
Run-In Period (2 Weeks)Received At Least 1 Dose of Study DrugOriginal Crossover Design - Placebo, Then Treprostinil0
Run-In Period (2 Weeks)Received At Least 1 Dose of Study DrugContingent Parallel Design - Treprostinil0
Run-In Period (2 Weeks)Received At Least 1 Dose of Study DrugContingent Parallel Design - Placebo0
Run-In Period (2 Weeks)COMPLETEDRun-In76
Run-In Period (2 Weeks)COMPLETEDOriginal Crossover Design - Treprostinil, Then Placebo0
Run-In Period (2 Weeks)COMPLETEDOriginal Crossover Design - Placebo, Then Treprostinil0
Run-In Period (2 Weeks)COMPLETEDContingent Parallel Design - Treprostinil0
Run-In Period (2 Weeks)COMPLETEDContingent Parallel Design - Placebo0
Run-In Period (2 Weeks)NOT COMPLETEDRun-In32
Run-In Period (2 Weeks)NOT COMPLETEDOriginal Crossover Design - Treprostinil, Then Placebo0
Run-In Period (2 Weeks)NOT COMPLETEDOriginal Crossover Design - Placebo, Then Treprostinil0
Run-In Period (2 Weeks)NOT COMPLETEDContingent Parallel Design - Treprostinil0
Run-In Period (2 Weeks)NOT COMPLETEDContingent Parallel Design - Placebo0

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

Next page

Sources 3

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
  • NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated
  • NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this list from software.

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT03496623/flow

API referenceFor AI assistants